The market has been neutral on Monopar Therapeutics Inc (MNPR) stock recently. MNPR gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.
Monopar Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on MNPR!
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With MNPR Stock Today?
Monopar Therapeutics Inc (MNPR) stock is trading at $2.00 as of 11:58 AM on Wednesday, Jun 15, a rise of $0.04, or 2.04% from the previous closing price of $1.96. The stock has traded between $2.00 and $2.42 so far today. Volume today is below average. So far 3,210 shares have traded compared to average volume of 10,739 shares.
More About Monopar Therapeutics Inc
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Click Here to get the full Stock Report for Monopar Therapeutics Inc stock.